Previous treatment decreases efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer
BackgroundPralsetinib is a selective RET inhibitor. The ARROW trial revealed that RET fusion-positive non-small-cell lung cancer (NSCLC) can benefit from pralsetinib with tolerable adverse events (AEs). However, the efficacy and safety of pralsetinib in real world has rarely been reported.Materials...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2025.1467871/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832587216565567488 |
|---|---|
| author | Lei Wang Yafei You Wenzhuo He Yu Hou Lan Li Li Wang Chang Jiang Jiahong Yi Yaoxiong Xia Liangping Xia |
| author_facet | Lei Wang Yafei You Wenzhuo He Yu Hou Lan Li Li Wang Chang Jiang Jiahong Yi Yaoxiong Xia Liangping Xia |
| author_sort | Lei Wang |
| collection | DOAJ |
| description | BackgroundPralsetinib is a selective RET inhibitor. The ARROW trial revealed that RET fusion-positive non-small-cell lung cancer (NSCLC) can benefit from pralsetinib with tolerable adverse events (AEs). However, the efficacy and safety of pralsetinib in real world has rarely been reported.Materials and methodsThis study reviewed the efficacy and safety of pralsetinib in RET fusion-positive NSCLC patients between March 2021 and December 2021. Progression-free survival (PFS) and overall survival (OS) were evaluated by a Kaplan-Meier analysis and log-rank test. A Cox regression model was performed to identify independent prognostic factors.ResultsA total of 28 patients were enrolled, and the median follow-up time was 18.1 months. The objective response rate and disease control rate of the whole cohort were 57.2% and 71.4%, respectively, and the median PFS and OS were 8.1 months [95% confidence interval (CI), 3.1–13.2] and 13.8 months (95% CI, 2.8–24.8), respectively. Baseline characteristics of the treatment naive group and pre-treated group were listed. The median PFS tended to be better in treatment naive group (18.3 vs. 8.0 months, P = 0.067), while the median OS were similar between the two groups (28.4 vs. 11.6 months, P = 0.308). Patients with Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 2 had worse median PFS comparing with those with ECOG PS score of 0–1 (3.8 vs. 12.6 months, P = 0.004). Besides, patients previously treated with platinum-based chemotherapy (PBC) also revealed worse median PFS comparing with those without previous PBC (8.0 vs. 18.6 months, P = 0.023). Furthermore, patients previously treated with anti-programmed death-1 (PD-1) antibody or multikinase inhibitors (MKIs) showed worse median OS compared with those without previous anti-PD-1 antibody (5.0 vs. 22.0 months, P = 0.002) or MKIs (6.2 vs. 28.4 months, P = 0.015). The most common AEs was increased aspartate aminotransferase (39.3%).ConclusionPralsetinib was effective in RET fusion-positive NSCLC with tolerable AEs in real-world practice. Efficacy of pralsetinib was decreased in patients previously treated with PBC, immunotherapy, or MKIs. |
| format | Article |
| id | doaj-art-608aac2410c94610b2c2dc78eb89c822 |
| institution | Kabale University |
| issn | 2296-858X |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Medicine |
| spelling | doaj-art-608aac2410c94610b2c2dc78eb89c8222025-01-24T16:01:40ZengFrontiers Media S.A.Frontiers in Medicine2296-858X2025-01-011210.3389/fmed.2025.14678711467871Previous treatment decreases efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancerLei Wang0Yafei You1Wenzhuo He2Yu Hou3Lan Li4Li Wang5Chang Jiang6Jiahong Yi7Yaoxiong Xia8Liangping Xia9Department of Radiotherapy, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Pecking University Cancer Hospital Yunnan, Kunming, Yunnan, ChinaThe Department of Clinical Oncology, The Seventh Affiliated Hospital, Sun Yat-Sen University, Shenzhen, Guangdong, ChinaDepartment of VIP Region, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, ChinaDepartment of Radiotherapy, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Pecking University Cancer Hospital Yunnan, Kunming, Yunnan, ChinaDepartment of Radiotherapy, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Pecking University Cancer Hospital Yunnan, Kunming, Yunnan, ChinaDepartment of Radiotherapy, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Pecking University Cancer Hospital Yunnan, Kunming, Yunnan, ChinaDepartment of VIP Region, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, ChinaDepartment of VIP Region, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, ChinaDepartment of Radiotherapy, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Pecking University Cancer Hospital Yunnan, Kunming, Yunnan, ChinaDepartment of VIP Region, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, ChinaBackgroundPralsetinib is a selective RET inhibitor. The ARROW trial revealed that RET fusion-positive non-small-cell lung cancer (NSCLC) can benefit from pralsetinib with tolerable adverse events (AEs). However, the efficacy and safety of pralsetinib in real world has rarely been reported.Materials and methodsThis study reviewed the efficacy and safety of pralsetinib in RET fusion-positive NSCLC patients between March 2021 and December 2021. Progression-free survival (PFS) and overall survival (OS) were evaluated by a Kaplan-Meier analysis and log-rank test. A Cox regression model was performed to identify independent prognostic factors.ResultsA total of 28 patients were enrolled, and the median follow-up time was 18.1 months. The objective response rate and disease control rate of the whole cohort were 57.2% and 71.4%, respectively, and the median PFS and OS were 8.1 months [95% confidence interval (CI), 3.1–13.2] and 13.8 months (95% CI, 2.8–24.8), respectively. Baseline characteristics of the treatment naive group and pre-treated group were listed. The median PFS tended to be better in treatment naive group (18.3 vs. 8.0 months, P = 0.067), while the median OS were similar between the two groups (28.4 vs. 11.6 months, P = 0.308). Patients with Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 2 had worse median PFS comparing with those with ECOG PS score of 0–1 (3.8 vs. 12.6 months, P = 0.004). Besides, patients previously treated with platinum-based chemotherapy (PBC) also revealed worse median PFS comparing with those without previous PBC (8.0 vs. 18.6 months, P = 0.023). Furthermore, patients previously treated with anti-programmed death-1 (PD-1) antibody or multikinase inhibitors (MKIs) showed worse median OS compared with those without previous anti-PD-1 antibody (5.0 vs. 22.0 months, P = 0.002) or MKIs (6.2 vs. 28.4 months, P = 0.015). The most common AEs was increased aspartate aminotransferase (39.3%).ConclusionPralsetinib was effective in RET fusion-positive NSCLC with tolerable AEs in real-world practice. Efficacy of pralsetinib was decreased in patients previously treated with PBC, immunotherapy, or MKIs.https://www.frontiersin.org/articles/10.3389/fmed.2025.1467871/fullRET fusionnon-small-cell lung cancerpralsetinibsurvival outcomesprognostic factors |
| spellingShingle | Lei Wang Yafei You Wenzhuo He Yu Hou Lan Li Li Wang Chang Jiang Jiahong Yi Yaoxiong Xia Liangping Xia Previous treatment decreases efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer Frontiers in Medicine RET fusion non-small-cell lung cancer pralsetinib survival outcomes prognostic factors |
| title | Previous treatment decreases efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer |
| title_full | Previous treatment decreases efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer |
| title_fullStr | Previous treatment decreases efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer |
| title_full_unstemmed | Previous treatment decreases efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer |
| title_short | Previous treatment decreases efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer |
| title_sort | previous treatment decreases efficacy of pralsetinib in ret fusion positive non small cell lung cancer |
| topic | RET fusion non-small-cell lung cancer pralsetinib survival outcomes prognostic factors |
| url | https://www.frontiersin.org/articles/10.3389/fmed.2025.1467871/full |
| work_keys_str_mv | AT leiwang previoustreatmentdecreasesefficacyofpralsetinibinretfusionpositivenonsmallcelllungcancer AT yafeiyou previoustreatmentdecreasesefficacyofpralsetinibinretfusionpositivenonsmallcelllungcancer AT wenzhuohe previoustreatmentdecreasesefficacyofpralsetinibinretfusionpositivenonsmallcelllungcancer AT yuhou previoustreatmentdecreasesefficacyofpralsetinibinretfusionpositivenonsmallcelllungcancer AT lanli previoustreatmentdecreasesefficacyofpralsetinibinretfusionpositivenonsmallcelllungcancer AT liwang previoustreatmentdecreasesefficacyofpralsetinibinretfusionpositivenonsmallcelllungcancer AT changjiang previoustreatmentdecreasesefficacyofpralsetinibinretfusionpositivenonsmallcelllungcancer AT jiahongyi previoustreatmentdecreasesefficacyofpralsetinibinretfusionpositivenonsmallcelllungcancer AT yaoxiongxia previoustreatmentdecreasesefficacyofpralsetinibinretfusionpositivenonsmallcelllungcancer AT liangpingxia previoustreatmentdecreasesefficacyofpralsetinibinretfusionpositivenonsmallcelllungcancer |